Forum Home Page [see Broadridge note below]

 The Shareholder ForumTM`

Fair Investor Access

This public program was initiated in collaboration with The Conference Board Task Force on Corporate/Investor Engagement and with Thomson Reuters support of communication technologies. The Forum is providing continuing reports of the issues that concern this program's participants, as summarized  in the January 5, 2015 Forum Report of Conclusions.

"Fair Access" Home Page

"Fair Access" Program Reference


Related Projects 2012-2019

For graphed analyses of company and related industry returns, see

Returns on Corporate Capital

See also analyses of

Shareholder Support Rankings


Forum distribution:

Activist invents partisan-moderated version of a shareholder forum


For a copy of the Pershing Square proxy filing for what is characterized as a shareholder meeting, as described in the article below, see

For subsequent observations, see


Source: Reuters Hedgeworld, May 15, 2014 column




No downside in Allergan 'meeting'

By Alison Frankel, Reuters

Thursday, May 15, 2014

Valeant Pharmaceuticals and its hostile takeover partner William Ackman of Pershing Square Capital Management have a phalanx of lawyers working on their $47 billion bid for Allergan – Kirkland & Ellis for Ackman; Sullivan & Cromwell and Skadden, Arps, Slate, Meagher & Flom for Valeant – so I don't know who deserves credit for the tactic they announced yesterday [May 13].

But whoever came up with the idea of holding an unofficial meeting and proxy vote to give Allergan shareholders an opportunity to urge the board to enter discussions with Valeant is quite a strategist. The Ackman/Valeant proxy is apparently the first time a hostile bidder has called for a non-binding straw poll of shareholders but I bet it won't be the last.

This is a win-win proposition for Ackman and Valeant, and here's why.

To start, the unofficial meeting and proxy vote permit Allergan's bidders to avoid two different sorts of obstacles: the company's board-friendly corporate framework and its recently-adopted poison pill.

Matt Levine at Bloomberg View did a great job Tuesday of explaining why Ackman, who holds about 9.7 percent of Allergan's stock through Pershing, can't talk directly to other shareholders for fear of crossing the 10 percent "beneficial ownership" threshold and triggering the poison pill. But the pill, Levine explained, has an exception for proxy solicitations like the one Ackman just launched.

So the unofficial proxy vote permits Ackman and Valeant to show Allergan what major investors think without actually talking to shareholders.

Plus, Ackman and Valeant don't have to worry about satisfying requirements in Allergan's corporate charter and bylaws for shareholder meetings.

An Advisory Vote

To convene a special meeting of shareholders – which they would have to do, since Allergan's regular annual meeting took place on May 6 – they'd have to obtain written consent from 25 percent of the shareholders. (Ronald Barusch of The Wall Street Journal's Dealpolitik detailed the special meeting process last week, after Valeant mentioned that it might go that route in a conference call with analysts.)

Shareholders can bind the corporation through votes at special meetings, though there's a chance Allergan would claim that a newly-adopted bylaw amendment bars shareholders from replacing directors through a meeting convened by written consent. (It's complicated, but one pension fund shareholder explained why in a complaint filed last week against Allergan's board in Delaware Chancery Court.)

None of that matters under Ackman's unofficial meeting strategy. The shareholder vote Ackman has launched doesn't seek to bind Allergan's board. It's just an advisory vote.

'Self-Serving Exercise'

So what does the vote accomplish? After all, even if a majority of Allergan shareholders vote yes on the Ackman resolution and request that the board enter discussions with Valeant – a high hurdle, considering that shareholders just elected nine board members by wide margins – the board is not bound by the vote.

Allergan's official statement on the Ackman proxy hints that the company won't be influenced by the outcome of what it called "a self-serving exercise" that ignores "the mechanism approved by the Allergan shareholders to call a special meeting."

But if Ackman and Valeant persuade even a sizable minority of Allergan shareholders that the board ought to talk to them, they'll have both a public relations victory and an argument that the board isn't living up to its fiduciary duties to shareholders.

You can already envision Ackman's future Delaware Chancery Court class, asserting that Allergan board members disregarded a shareholder directive to explore Valeant's offer.

I'm not saying Ackman would win the case based just on an advisory vote, but I'm sure Allergan's directors and their lawyers at Latham & Watkins will be thinking about the prospect of litigation when they decide how to respond to the proxy vote.

That's the considerable upside for Valeant and Ackman if the vote goes their way: forcing talks through P.R. and the board's fear of litigation and liability. But what if Ackman's resolution gets only weak support from Allergan's shareholders?

Here's the real beauty of Ackman's proxy play: Valeant probably wouldn't even have to report a bad outcome to the Securities and Exchange Commission, according to former SEC lawyer Seth Taube of Baker Botts.

Obviously, the Allergan bid is material to Valeant, a public company. But an unfavorable result in a non-binding, unofficial shareholder vote, Taube said, is probably not material. "I would think it's not a disclosable risk," Taube said.

He also pointed out that the shareholders who vote on Ackman's resolution are likely to be those who support it. So there ought to be ways for Ackman and Valeant to spin the outcome even if they obtain support from a relatively small number of shareholders, by presenting yes votes as a percentage of the total votes rather than the total float.

You really can't ask for a smarter strategy than one that lets Ackman and Valeant reach out to other shareholders without triggering the pill and positions them for a litigation challenge while costing them nothing more than the expense of a proxy contest. No wonder Matt Levine at Bloomberg has called the Allergan takeover battle "a weird textbook for The Future of Mergers & Acquisitions."

Alison Frankel

The opinions expressed here are those of Alison Frankel, a columnist for Reuters.


Story Copyright © 1999-2014 Reuters HedgeWorld All rights reserved.


This Forum program was open, free of charge, to anyone concerned with investor interests in the development of marketplace standards for expanded access to information for securities valuation and shareholder voting decisions. As stated in the posted Conditions of Participation, the purpose of this public Forum's program was to provide decision-makers with access to information and a free exchange of views on the issues presented in the program's Forum Summary. Each participant was expected to make independent use of information obtained through the Forum, subject to the privacy rights of other participants.  It is a Forum rule that participants will not be identified or quoted without their explicit permission.

This Forum program was initiated in 2012 in collaboration with The Conference Board and with Thomson Reuters support of communication technologies to address issues and objectives defined by participants in the 2010 "E-Meetings" program relevant to broad public interests in marketplace practices. The website is being maintained to provide continuing reports of the issues addressed in the program, as summarized in the January 5, 2015 Forum Report of Conclusions.

Inquiries about this Forum program and requests to be included in its distribution list may be addressed to

The information provided to Forum participants is intended for their private reference, and permission has not been granted for the republishing of any copyrighted material. The material presented on this web site is the responsibility of Gary Lutin, as chairman of the Shareholder Forum.

Shareholder Forum™ is a trademark owned by The Shareholder Forum, Inc., for the programs conducted since 1999 to support investor access to decision-making information. It should be noted that we have no responsibility for the services that Broadridge Financial Solutions, Inc., introduced for review in the Forum's 2010 "E-Meetings" program and has since been offering with the “Shareholder Forum” name, and we have asked Broadridge to use a different name that does not suggest our support or endorsement.